Managing recurrent portal steal in auxiliary liver transplantation for non-cirrhotic metabolic liver disease.

While the early impediments in this technique may have been overcome, in the absence of any realistic clinical application gene therapy, the debate of long-term phenotypic metabolic correction for NCMLD by APOLT needs to be revisited.